{"title":"基于 1,3,4-噻二唑和 1,3-噻唑烷-4-酮的新二元杂环分子的合成和抗增殖效力:体外细胞抗癌研究","authors":"Avik Maji, Ambati Himaja, Sripathi Nikhitha, Soumitra Rana, Abhik Paul, Ajeya Samanta, Uday Shee, Chhanda Mukhopadhyay, Balaram Ghosh and Tapan Kumar Maity","doi":"10.1039/D4MD00279B","DOIUrl":null,"url":null,"abstract":"<p >Herein, we report the synthesis and anticancer properties of 21 new 1,3,4-thiadiazole-2-yl-imino-thiazolidine-4-one containing binary heterocyclic molecules. Cytotoxicity of the synthesized molecules was evaluated on various <em>in vitro</em> cancer cell lines (MCF-7, PC3, 4T1, MDA-MB-231, and MOC2) and normal human embryonic cell lines (HEK-293) <em>via</em> MTT assay. The cytotoxicity data of developed compounds was compared with the reference anticancer molecule <strong>BG45</strong>, a selective inhibitor of the HDAC3 enzyme. All compounds showed a significant cytotoxic effect higher than <strong>BG45</strong> on tested cancer cell lines. Moreover, the compounds exhibited better selectivity on cancer cells than on normal cells. Among the molecules, compound <strong>6e</strong> is the most potent in cytotoxic activity on MCF-7 cell lines (IC<small><sub>50</sub></small> value of 3.85 μM). Additional mechanistic investigation revealed that compound <strong>6e</strong> promotes apoptosis (25.3%) and G0/G1 phase cell cycle arrest of MCF-7 cells. Also, compound <strong>6e</strong> induces intracellular ROS accumulation and subsequent nuclear fragmentation. Hence, this research finds new hybrid molecules active against <em>in vitro</em> cancer cells.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 9","pages":" 3057-3069"},"PeriodicalIF":3.5970,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthesis and antiproliferative potency of 1,3,4-thiadiazole and 1,3-thiazolidine-4-one based new binary heterocyclic molecules: in vitro cell-based anticancer studies†\",\"authors\":\"Avik Maji, Ambati Himaja, Sripathi Nikhitha, Soumitra Rana, Abhik Paul, Ajeya Samanta, Uday Shee, Chhanda Mukhopadhyay, Balaram Ghosh and Tapan Kumar Maity\",\"doi\":\"10.1039/D4MD00279B\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Herein, we report the synthesis and anticancer properties of 21 new 1,3,4-thiadiazole-2-yl-imino-thiazolidine-4-one containing binary heterocyclic molecules. Cytotoxicity of the synthesized molecules was evaluated on various <em>in vitro</em> cancer cell lines (MCF-7, PC3, 4T1, MDA-MB-231, and MOC2) and normal human embryonic cell lines (HEK-293) <em>via</em> MTT assay. The cytotoxicity data of developed compounds was compared with the reference anticancer molecule <strong>BG45</strong>, a selective inhibitor of the HDAC3 enzyme. All compounds showed a significant cytotoxic effect higher than <strong>BG45</strong> on tested cancer cell lines. Moreover, the compounds exhibited better selectivity on cancer cells than on normal cells. Among the molecules, compound <strong>6e</strong> is the most potent in cytotoxic activity on MCF-7 cell lines (IC<small><sub>50</sub></small> value of 3.85 μM). Additional mechanistic investigation revealed that compound <strong>6e</strong> promotes apoptosis (25.3%) and G0/G1 phase cell cycle arrest of MCF-7 cells. Also, compound <strong>6e</strong> induces intracellular ROS accumulation and subsequent nuclear fragmentation. Hence, this research finds new hybrid molecules active against <em>in vitro</em> cancer cells.</p>\",\"PeriodicalId\":88,\"journal\":{\"name\":\"MedChemComm\",\"volume\":\" 9\",\"pages\":\" 3057-3069\"},\"PeriodicalIF\":3.5970,\"publicationDate\":\"2024-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedChemComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00279b\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00279b","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
摘要
在此,我们报告了 21 种新的 1,3,4-噻二唑-2-基-亚氨基噻唑烷-4-酮二元杂环分子的合成和抗癌特性。通过 MTT 试验评估了合成分子对各种体外癌细胞株(MCF-7、PC3、4T1、MDA-MB-231 和 MOC2)和正常人胚胎细胞株(HEK-293)的细胞毒性。所开发化合物的细胞毒性数据与参考抗癌分子 BG45(一种 HDAC3 酶的选择性抑制剂)进行了比较。在测试的癌细胞系中,所有化合物的细胞毒性效果均明显高于 BG45。此外,这些化合物对癌细胞的选择性优于正常细胞。在这些分子中,化合物 6e 对 MCF-7 细胞株的细胞毒性最强(IC50 值为 3.85 μM)。其他机理研究表明,化合物 6e 能促进 MCF-7 细胞凋亡(25.3%)和 G0/G1 期细胞周期停滞。此外,化合物 6e 还能诱导细胞内 ROS 的积累和随后的核破碎。因此,这项研究发现了对体外癌细胞具有活性的新混合分子。
Synthesis and antiproliferative potency of 1,3,4-thiadiazole and 1,3-thiazolidine-4-one based new binary heterocyclic molecules: in vitro cell-based anticancer studies†
Herein, we report the synthesis and anticancer properties of 21 new 1,3,4-thiadiazole-2-yl-imino-thiazolidine-4-one containing binary heterocyclic molecules. Cytotoxicity of the synthesized molecules was evaluated on various in vitro cancer cell lines (MCF-7, PC3, 4T1, MDA-MB-231, and MOC2) and normal human embryonic cell lines (HEK-293) via MTT assay. The cytotoxicity data of developed compounds was compared with the reference anticancer molecule BG45, a selective inhibitor of the HDAC3 enzyme. All compounds showed a significant cytotoxic effect higher than BG45 on tested cancer cell lines. Moreover, the compounds exhibited better selectivity on cancer cells than on normal cells. Among the molecules, compound 6e is the most potent in cytotoxic activity on MCF-7 cell lines (IC50 value of 3.85 μM). Additional mechanistic investigation revealed that compound 6e promotes apoptosis (25.3%) and G0/G1 phase cell cycle arrest of MCF-7 cells. Also, compound 6e induces intracellular ROS accumulation and subsequent nuclear fragmentation. Hence, this research finds new hybrid molecules active against in vitro cancer cells.
期刊介绍:
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.